Cargando…

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability

Anagliptin is a novel dipeptidyl peptidase-4 inhibitor that has been available in Japan since 2012. Because anagliptin is not generally used in countries other than Japan, there are only a small number of reports investigating the effects of anagliptin. In the present article, we review the safety a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishio, Shinya, Abe, Mariko, Ito, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370682/ https://www.ncbi.nlm.nih.gov/pubmed/25834461 http://dx.doi.org/10.2147/DMSO.S54679

Ejemplares similares

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Chiba, Yukari, et al.
Publicado: (2018)

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
por: Kurozumi, Akira, et al.
Publicado: (2017)

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus
por: Nomura, Shosaku, et al.
Publicado: (2023)

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial
por: Onoue, Takeshi, et al.
Publicado: (2020)

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
por: Hirai, Hiroyuki, et al.
Publicado: (2019)

Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial
por: Iijima, Takahiro, et al.
Publicado: (2020)

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability
por: Pan, CY, et al.
Publicado: (2013)

Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study
por: Kishimoto, Miyako, et al.
Publicado: (2014)

Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study
por: Ito, Hiroyuki, et al.
Publicado: (2016)

Dipeptidyl peptidase‐4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes
por: Abe, Takahiro, et al.
Publicado: (2021)

Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
por: Ito, Hiroyuki, et al.
Publicado: (2014)

Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013
por: Ito, Hiroyuki, et al.
Publicado: (2016)

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
por: Chihara, Atsuko, et al.
Publicado: (2019)

Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes
por: Ito, Hiroyuki, et al.
Publicado: (2017)

Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
por: Hamasaki, Hidetaka, et al.
Publicado: (2018)

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial
por: Ueda, Shinichiro, et al.
Publicado: (2018)

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
por: Furuhashi, Masato, et al.
Publicado: (2022)

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats
por: Kaya, Daisuke, et al.
Publicado: (2019)

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
por: Kitada, Munehiro, et al.
Publicado: (2017)

Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
por: Rogalski, Christina
Publicado: (2015)

Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer
por: Lousberg, Laurence, et al.
Publicado: (2017)

Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability
por: Abrouk, Michael, et al.
Publicado: (2016)

Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
por: Desouza, Cyrus V., et al.
Publicado: (2010)

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
por: Guedes, Erika Paniago, et al.
Publicado: (2013)

The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury
por: Li, Qi, et al.
Publicado: (2017)

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2022)

Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
Publicado: (2017)

Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
por: Aziz, Kamran MA
Publicado: (2015)

Flow Mediated Dilatation Is Reduced with the Progressive Stages of Glomerular Filtration Rate and Albuminuria in Type 2 Diabetic Patients without Coronary Heart Disease
por: Ito, Hiroyuki, et al.
Publicado: (2015)

Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport
por: Goto, Moritaka, et al.
Publicado: (2018)

Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses
por: Caperton, Caroline, et al.
Publicado: (2011)

Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
por: Jain, Rajeev
Publicado: (2015)

Efficacy, safety, and patient acceptability of the Essure™ procedure
por: Lessard, Collette R, et al.
Publicado: (2011)

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
por: Furuhashi, Masato, et al.
Publicado: (2020)

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2020)

Effects of anagliptin on the stress induced accelerated senescence of human umbilical vein endothelial cells
por: Kang, Seon Mee, et al.
Publicado: (2021)

High-fat diet feeding significantly attenuates anagliptin-induced regeneration of islets of Langerhans in streptozotocin-induced diabetic mice
por: Shinjo, Takanori, et al.
Publicado: (2015)

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability
por: Cho, Hee Ju, et al.
Publicado: (2014)

Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
por: Inderjeeth, Charles A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ggc1f17qe5uvemg1ebjoj1jbim